Domo 'Regado': $51M to Fund REG1 Phase III in Thrombosis
Regado Biosciences Inc.'s hefty Series E round on the brink of a Phase III with its anticoagulant REG1 is one of the larger private financings of the year, and the $51 million bets mainly on an approach to clotbusting that the company hopes will get around the bleeding risks that have beset others.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter